Pharmabiz1d
Lipella Pharma completes dosing for first cohort in phase 2a trial of LP-310 for oral lichen planus
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company focused on innovative therapies for serious diseases with significant unmet needs, announced the completion of dosing for the first ...
Pharmabiz1d
China NMPA approves Merck’s Welireg to treat adult patients with certain types of von Hippel-Lindau disease-associated tumours
Merck, known as MSD outside of the United States and Canada, announced that the National Medical Products Administration (NMPA) in China has approved Welireg (belzutifan), for the treatment of adult ...
Pharmabiz1d
Bioretec inks sales and distribution pact to speed-up the commercialization of RemeOs Trauma Screw in US market
Bioretec Ltd, a pioneering company dedicated to advancing biodegradable orthopaedic implants, is moving ahead with the next phase of the commercialization of its innovative RemeOs Trauma Products in ...
Pharmabiz1d
CapeStart introduces MadeAi, a GenAI-enabled platform for life sciences that transforms literature review and other applications
CapeStart introduces MadeAi, a GenAI-enabled platform for life sciences that transforms literature review and other applications: Barcelona, Spain Saturday, November 23, 2024, 17: ...
Pharmabiz1d
Zai Lab, Pfizer enter collaboration on novel antibacterial drug Xacduro in mainland China
Zai Lab (Zai Lab) and Pfizer announced a strategic collaboration for the novel antibacterial drug Xacduro (sulbactam-durlobactam) in mainland China. Pfizer’s affiliated companies will be exclusively ...
Pharmabiz1d
SOPHiA GENETICS launches MSK-IMPACT powered with SOPHiA DDM at AMP 2024
SOPHiA GENETICS launches MSK-IMPACT powered with SOPHiA DDM at AMP 2024: Boston, Massachusetts Saturday, November 23, 2024, 16:00 Hrs [IST] SOPHiA GENETICS, a cloud-native healthc ...
Pharmabiz1d
Japan’s MHLW grants expanded indication approval to GSK’s RSV vaccine, Arexvy for adults aged 50-59 at increased risk of severe RSV disease
GSK plc announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved a regulatory application to extend the indication of Arexvy (respiratory syncytial virus vaccine, recombinant ...
Pharmabiz1d
Biotechnology to spur avenues in precision bio-therapeutics & bio-based chemicals
Union government is emphasising that the biotechnology sector’s thrust should be towards twin technologies. One is digital tech and the other is green tech which will help it transition towards ...
Pharmabiz1d
NPPA revises ceiling price of atorvastatin 10 mg based on review order
The National Pharmaceutical Pricing Authority (NPPA) has released the recalculated ceiling price of cholesterol lowering drug atorvastatin 10 mg as per the instructions of the review authority under ...
Pharmabiz1d
Philips introduces next-generation BlueSeal helium-free MRI system, integrated with AI-enabled Smart Reading
Philips introduces next-generation BlueSeal helium-free MRI system, integrated with AI-enabled Smart Reading: Amsterdam, the Netherlands Saturday, November 23, 2024, 13:00 Hrs [IS ...
Pharmabiz1d
Leads Biolabs receives US FDA orphan drug designation for anti-PD-L1/4-1BB bispecific antibody, LBL-024 for treatment of neuroendocrine cancer
Leads Biolabs receives US FDA orphan drug designation for anti-PD-L1/4-1BB bispecific antibody, LBL-024 for treatment of neuroendocrine cancer: Nanjing, China Saturday, November 2 ...
Pharmabiz1d
Zenyaku Kogyo receives Japanese approval for anti-CD20 monoclonal antibody, Rituxan to treat chronic ITP in children
Zenyaku Kogyo receives Japanese approval for anti-CD20 monoclonal antibody, Rituxan to treat chronic ITP in children: Tokyo Saturday, November 23, 2024, 10:00 Hrs [IST] Zenyaku Ko ...